Google
INDP — INDAPTUS THERAPEUTICS INC (Healthcare >> Biotechnology)
INDP FAQ
What is INDP's ROE?
INDAPTUS THERAPEUTICS INC reports a Return on Equity (ROE) of -1,511.20%.
What is INDP's dividend yield?
INDAPTUS THERAPEUTICS INC offers a dividend yield of 0.00%.
What is INDP's Deepscope Quality Score?
Deepscope rates INDP's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy INDP?
Deepscope's AI Timing Score for INDP is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does INDP belong to?
INDAPTUS THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.75
Price
2.54
(114.93%)
Day Change
|
|
|---|
INDP, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.75 |
| PBV / Sector |
195.11 / 4.58
|
| Earning Per Share | -0.37 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
9.97 M
|
| Average 1W Daily Value |
39.47 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:27 |
| Symbol | INDP |
| Name | INDAPTUS THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 113.24 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 243.47 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Three Columbus Circle, New York, NY, United States, 10019
Phone: 646 427 2727
Website: https://indaptusrx.com
Sector: Healthcare >> Biotechnology
Description: Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
